Dongcheng Pharmaceutical: Subsidiary company receives notice of approval for drug clinical trials.

Dongcheng Pharmaceutical announced on August 22 that its subsidiary company, LNC PHARMA PTE. LTD., received the Drug Clinical Trial Approval Letter for 225Ac-LNC1011 injection issued by the Food and Drug Administration of the United States on August 22, and will soon conduct Phase I clinical trials. The drug is intended for the treatment of advanced prostate cancer patients with PSMA-positive expression.